|
Male (n)
|
86% (n = 150)
|
79% (n = 86)
|
|
Age in years, Median (IQR)
|
39 (33; 46)
|
41 (37; 50)
|
|
Height in cm, Median, (IQR)
|
176 (172; 183)
|
178 (170; 182)
|
|
Weight in kg, Median (IQR)
|
72 (65; 79)
|
72 (65; 80)
|
|
Hepatitis B coinfection
|
5% (n = 9)
|
2% (n = 2)
|
|
Hepatitis C coinfection
|
12% (n = 21)
|
10% (n = 11)
|
|
Infection mode
| | |
|
MSM
|
61%
|
59%
|
|
Heterosexual
|
19%
|
17%
|
|
IVDU
|
6%
|
6%
|
|
Not specified
|
14%
|
18%
|
|
Race
| | |
|
Caucasian
|
85%
|
78%
|
|
African
|
8%
|
11%
|
|
Asian
|
3%
|
5%
|
|
Not specified
|
4%
|
6%
|
|
CDC stage
| | |
|
A
|
38%
|
29%
|
|
B
|
33%
|
51%
|
|
C
|
27%
|
17%
|
|
Not specified
|
2%
|
3%
|
|
Time since first diagnosis in years, Median (IQR)
|
1 (0; 4)
|
9 (5; 13)
|
|
Time since first ART in months, Median (IQR)
|
-
|
79 (37; 104)
|
|
Number of previous regimen, Median (IQR)
|
-
|
3 (2; 4)
|
|
Treatment interruption before start of new regimen
|
-
|
28% (n = 30)
|
|
Duration of treatment interruption in months, Median (IQR)
|
-
|
24 (6; 40)
|
|
HIV RNA (copies/mL), Median (IQR)
|
117,000
|
3,433
|
| |
(36,548; 336,000)
|
(92; 34,384)
|
|
CD4-count (cells/mm
3
) Median (IQR)
|
196 (82; 284)
|
319 (204; 478)
|
